Galectin Therapeutics (GALT) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	001-31791
Entity Registrant Name	GALECTIN THERAPEUTICS INC.
Entity Central Index Key	0001133416
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	04-3562325
Entity Address, Address Line One	4960 Peachtree Industrial Blvd.
Entity Address, Address Line Two	Suite 240
Entity Address, City or Town	Norcross
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30071
City Area Code	678
Local Phone Number	620 -3186
Title of 12(b) Security	Common Stock
Trading Symbol	GALT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,426,005

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,831	$ 39,648
Prepaid expenses and other current assets	1,290	2,172
Total current assets	17,121	41,820
Other assets	793	7
Total assets	17,914	41,827
Current liabilities:
Accounts payable	2,352	1,805
Accrued expenses and other	7,236	7,163
Accrued dividends payable	0	65
Total current liabilities	9,588	9,033
Convertible note payable and accrued interest, net of debt discount - related party (Note 3)	29,734	29,048
Derivative liability (Note 4)	850	1,130
Other liabilities	77	0
Total liabilities	40,249	39,211
Commitments and contingencies (Note 10)
Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at September 30, 2022 and December 31, 2021, redemption value: $8,309,000, liquidation value: $1,760,000 at September 30, 2022	1,723	1,723
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at September 30, 2022 and December 31, 2021, respectively	0	0
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,260,000 and 1,302,500 issued and outstanding at September 30, 2022 and December 31, 2021, respectively; liquidation value $1,260,000 and $1,302,500 at September 30, 2022 and December 31, 2021, respectively	510	527
Common stock, $0.001 par value; 150,000,000 shares authorized at September 30, 2022 and December 31, 2021, 59,426,005 and 59,341,305 issued and outstanding at September 30, 2022 and December 31, 2021, respectively	59	59
Additional paid-in capital	274,241	271,001
Retained deficit	(298,868)	(270,694)
Total stockholders' equity (deficit)	(24,058)	893
Total liabilities, redeemable convertible preferred stock and stockholders' equity	$ 17,914	$ 41,827

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in shares)	1,000	1,000
Series C 6% super dividend redeemable convertible preferred stock, shares issued (in shares)	176	176
Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in shares)	176	176
Series C 6% super dividend redeemable convertible preferred stock, redemption value	$ 8,309,000
Series C 6% super dividend redeemable convertible preferred stock liquidation value	$ 1,760,000
Stockholders' equity (deficit):
Undesignated stock, par value (in dollars per share)	$ 0.01	$ 0.01
Undesignated stock, shares authorized (in shares)	20,000,000	20,000,000
Undesignated stock, shares designated (in shares)	20,000,000	20,000,000
Series A 12% convertible preferred stock, shares authorized (in shares)	1,742,500	1,742,500
Series A 12% convertible preferred stock, shares issued (in shares)	1,260,000	1,302,500
Series A 12% convertible preferred stock, shares outstanding (in shares)	1,260,000	1,302,500
Series A 12% convertible preferred stock, liquidation value	$ 1,260,000	$ 1,302,500
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	59,426,005	59,341,305
Common stock, outstanding (in shares)	59,426,005	59,341,305

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 6,598	$ 6,613	$ 22,730	$ 17,962
General and administrative	1,524	1,631	4,989	4,792
Total operating expenses	8,122	8,244	27,719	22,754
Total operating loss	(8,122)	(8,244)	(27,719)	(22,754)
Other income (expense):
Interest income	18	1	22	3
Interest expense	(269)	(111)	(725)	(217)
Change in fair value of derivative	(224)	(166)	280	(338)
Total other income (expense)	(475)	(276)	(423)	(552)
Net loss	(8,597)	(8,520)	(28,142)	(23,306)
Preferred stock dividends	16	(37)	(32)	(104)
Net loss applicable to common stockholders	$ (8,581)	$ (8,557)	$ (28,174)	$ (23,410)
Net loss per common share - basic (in dollars per share)	$ (0.14)	$ (0.14)	$ (0.47)	$ (0.4)
Net loss per common share - diluted (in dollars per share)	$ (0.14)	$ (0.14)	$ (0.47)	$ (0.4)
Weighted average common shares outstanding - basic (in shares)	59,396	59,290	59,380	58,253
Weighted average common shares outstanding - diluted (in shares)	59,396	59,290	59,380	58,253

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,597)	$ (8,520)	$ (28,142)	$ (23,306)
Adjustments to reconcile net loss to net cash flows from operating activities:
Stock-based compensation expense			2,186	1,422
Amortization of right to use lease asset			24	30
Non-cash interest expense			276	118
Change in fair value of derivative			(280)	338
Changes in operating assets and liabilities:
Prepaid expenses and other assets			772	925
Accounts payable, accrued expenses and other liabilities			899	3,017
Accrued interest on convertible notes payable - related party			448	99
Net cash flows from operating activities			(23,817)	(17,357)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from convertible note payable - related party			0	20,000
Net proceeds from issuance of common stock			0	6,815
Net cash flows from financing activities			0	26,815
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS			(23,817)	9,458
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			39,648	27,142	$ 27,142
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 15,831	$ 36,600	15,831	36,600	$ 39,648
NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock			32	104
Fair value of derivative related to related party convertible note payable			0	853
Reclassification of accrued bonus to additional paid in capital			200	60
Noncash right to use lease asset			111	0
Common stock purchase warrants issued in connection with related party line of credit			$ 738	$ 0

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Preferred Stock [Member] Series A 12% Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Deficit [Member]	Total
Beginning balance at Dec. 31, 2020					$ 1,723
Beginning balance (in shares) at Dec. 31, 2020					176
Ending balance at Sep. 30, 2021					$ 1,723
Ending balance (in shares) at Sep. 30, 2021					176
Beginning balance at Dec. 31, 2020	$ 527	$ 56	$ 261,883	$ (239,996)	$ 22,470
Beginning balance (in shares) at Dec. 31, 2020	1,302,500	57,077,055
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			78	(40)	38
Series A 12% convertible preferred stock dividend (in shares)		26,050
Series C super dividend redeemable convertible preferred stock dividend			92	(65)	27
Series C super dividend redeemable convertible preferred stock dividend (in shares)		31,112
Issuance of common stock		$ 1	3,863		3,864
Issuance of common stock (in shares)		845,214
Issuance of common stock for exercise of warrants and options		$ 2	2,949		2,951
Issuance of common stock for exercise of warrants and options (in shares)		1,329,181
Stock-based compensation expense			1,482		1,482
Stock-based compensation expense (in shares)		32,693
Net loss				(23,306)	(23,306)
Ending balance at Sep. 30, 2021	$ 527	$ 59	270,347	(263,407)	7,526
Ending balance (in shares) at Sep. 30, 2021	1,302,500	59,341,305
Ending balance at Sep. 30, 2021					$ 1,723
Ending balance (in shares) at Sep. 30, 2021					176
Beginning balance at Jun. 30, 2021	$ 527	$ 59	269,657	(254,850)	$ 15,393
Beginning balance (in shares) at Jun. 30, 2021	1,302,500	59,275,031
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			50	(11)	39
Series A 12% convertible preferred stock dividend (in shares)		13,025
Series C super dividend redeemable convertible preferred stock dividend			53	(26)	27
Series C super dividend redeemable convertible preferred stock dividend (in shares)		13,512
Issuance of common stock for exercise of warrants and options (in shares)		39,737
Stock-based compensation expense			587		587
Net loss				(8,520)	(8,520)
Ending balance at Sep. 30, 2021	$ 527	$ 59	270,347	(263,407)	7,526
Ending balance (in shares) at Sep. 30, 2021	1,302,500	59,341,305
Beginning balance at Dec. 31, 2021					$ 1,723
Beginning balance (in shares) at Dec. 31, 2021					176
Ending balance at Sep. 30, 2022					$ 1,723
Ending balance (in shares) at Sep. 30, 2022					176
Beginning balance at Dec. 31, 2021	$ 527	$ 59	271,001	(270,694)	$ 893
Beginning balance (in shares) at Dec. 31, 2021	1,302,500	59,341,305
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			41	(2)	39
Series A 12% convertible preferred stock dividend (in shares)		25,625
Series C super dividend redeemable convertible preferred stock dividend			58	(30)	28
Series C super dividend redeemable convertible preferred stock dividend (in shares)		35,200
Issuance of common stock from conversion of Series A convertible preferred stock	$ (17)		17
Issuance of common stock from conversion of Series A convertible preferred stock (in shares)	(42,500)	7,287
Issuance of common stock purchase warrants from related party line of credit			738		738
Accrued bonus paid in stock			200		200
Stock-based compensation expense			2,186		2,186
Stock-based compensation expense (in shares)		16,588
Net loss				(28,142)	(28,142)
Ending balance at Sep. 30, 2022	$ 510	$ 59	274,241	(298,868)	(24,058)
Ending balance (in shares) at Sep. 30, 2022	1,260,000	59,426,005
Ending balance at Sep. 30, 2022					$ 1,723
Ending balance (in shares) at Sep. 30, 2022					176
Beginning balance at Jun. 30, 2022	$ 510	$ 59	272,772	(290,287)	$ (16,946)
Beginning balance (in shares) at Jun. 30, 2022	1,302,500	59,395,805
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			21	18	39
Series A 12% convertible preferred stock dividend (in shares)		12,600
Series C super dividend redeemable convertible preferred stock dividend			29	(2)	27
Series C super dividend redeemable convertible preferred stock dividend (in shares)		17,600
Issuance of common stock purchase warrants from related party line of credit			738		738
Stock-based compensation expense			681		681
Net loss				(8,597)	(8,597)
Ending balance at Sep. 30, 2022	$ 510	$ 59	$ 274,241	$ (298,868)	$ (24,058)
Ending balance (in shares) at Sep. 30, 2022	1,260,000	59,426,005

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Basis of Presentation [Abstract]
Basis of Presentation	1. Basis of Presentation Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions. The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of September 30, 2022 and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2021 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2021. The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2022, the company had $15,831,000 of unrestricted cash and cash equivalents available to fund future operations. In July 2022, the Company entered into a $60 million unsecured line of credit financing with its chairman, Richard E. Uihlein (See Note 5). The Company believes there is sufficient cash, including availability of the line of credit, to fund currently planned operations at least through December 31, 2024. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved. The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.

Accrued Expenses and Other

Accrued Expenses and Other	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other [Abstract]
Accrued Expenses and Other	2. Accrued Expenses and Other Accrued expenses consist of the following: September 30, December 31, 2021 (in thousands) Legal and accounting fees $ 123 $ 68 Accrued compensation 751 728 Lease liability 39 8 Accrued research and development costs and other 6,323 6,359 Total $ 7,236 $ 7,163 Research and development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.

Convertible Notes Payable - Rel

Convertible Notes Payable - Related Party	9 Months Ended
	Sep. 30, 2022
Convertible Notes Payable - Related Party [Member]
Debt Instrument [Line Items]
Convertible Notes Payable - Related Party	3. Convertible Notes Payable – Related Party On April 16, 2021, the Company and Richard E. Uihlein entered into a debt financing arrangement whereby Mr. Uihlein loaned $10,000,000 to Company. In consideration for the loan, the Company issued a convertible promissory note (the “April Note”) in the principal amount of ten million dollars. The April Note has a maturity date of April 16, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April Note bears interest at the rate of two percent (2%) per annum, compounded annually. For the three and nine months ended September 30, 2022, approximately $50,000 and $150,000 of interest expense, respectively, was accrued and included with the principal in the financial statements. Inception to September 30, 2022, approximately $292,000 of interest expense has been accrued and included with the principal balance. The April Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the April Note at its inception. The fair value of the contingent interest derivative liability was $420,000 and $373,000 at note inception (April 16, 2021) and September 30 September 30 September 30 for the for the nine months ended September 30 On September 17, 2021, the Company and Mr. Uihlein entered into a loan agreement in the aggregate of $20,000,000 (the “Loan Agreement”) to be funded in two closings and evidenced by two separate unsecured convertible promissory notes. The first of the two promissory notes was also executed and delivered on September 17, 2021, (the “September Note”) to evidence the first loan in the principal amount of $10,000,000. The second closing under the Loan Agreement for the remaining $10,000,000 occurred on December 20, 2021. The September Note has a maturity date of September 17, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September Note bears interest at the rate of two percent (2%) per annum, compounded annually. For the three and nine months ended September 30, 2022, approximately $50,000 and $150,000, respectively, of interest expense was accrued and included with the principal in the financial statements. Inception to September 30, 2022, approximately $207,000 of interest expense has been accrued and included with the principal balance. The September Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the September Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the September Note at its inception. The fair value of the contingent interest derivative liability was $433,000 and $177,000 at note inception (September 17, 2021) and September 30 September 30 September 30 September 30 On December 20, 2021, the second of the two promissory notes under the Loan Agreement was executed and delivered, (the “December Note”) to evidence the second loan in the principal amount of $10,000,000. The December Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $5.43 per share at the option of the noteholder. The December Note bears interest at the rate of two percent (2%) per annum, compounded annually. The December Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the December Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the December Note at its inception. The fair value of the contingent interest derivative liability was $415,000 and $301,000 at note inception (December 20, 2021) and September 30 September 30 September 30 30 The Company’s contractual cash obligations related to the outstanding convertible notes payable is a repayment of the April Note of the $10,000,000 plus accrued interest on April 16, 2025 and a repayment of the September Note of the $10,000,000 plus accrued interest on September 17, 2025 and a repayment of the December Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option of the noteholder.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 2 assets or liabilities at Assets and liabilities measured and recorded at fair value on a recurring basis at September 30, 2022 were as follows: Level 1 Level 2 Level 3 Total Derivative Liability – Contingent Interest April Note $ — $ — $ 373,000 $ 373,000 Derivative Liability – Contingent Interest September Note $ — $ — $ 177,000 $ 177,000 Derivative Liability – Contingent Interest December Note $ — $ — $ 301,000 $ 301,000 The April Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: September 30, Inception 2022 Stock Price $ 2.19 $ 1.63 Conversion Price of conversion feature $ 5.00 $ 5.00 Term 4 years 2.54 years Risk Free Interest Rate 0.59 % 4.24 % Credit Adjusted Discount Rate 7.60 % 17.42 % Volatility 88 % 83 % Dividend Rate 0 % 0 % The roll forward of the April Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of April convertible note payable – related party 420,000 Fair Value Adjustment 75,000 Balance – December 31, 2021 $ 495,000 Fair Value Adjustment (122,000 ) Balance – September 30, 2022 $ 373,000 The September Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: Inception September 30 2022 Stock Price $ 4.06 $ 1.63 Conversion Price of conversion feature $ 8.64 $ 8.64 Term 4 years 2.97 Risk Free Interest Rate 0.68 % 4.25 % Credit Adjusted Discount Rate 7.59 % 17.42 % Volatility 91 % 83 % Dividend Rate 0 % 0 % The roll forward of the September Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of September convertible note payable – related party 433,000 Fair Value Adjustment (183,000 ) Balance – December 31, 2021 $ 250,000 Fair Value Adjustment (73,000 ) Balance – September 30 $ 177,000 The December Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: September 30 Inception 2022 Stock Price $ 2.32 $ 1.63 Conversion Price of conversion feature $ 5.43 $ 5.43 Term 4 years 3.22 years Risk Free Interest Rate 1.04 % 4.24 % Credit Adjusted Discount Rate 8.54 % 17.42 % Volatility 86 % 81 % Dividend Rate 0 % 0 % The roll forward of the December Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of September convertible note payable – related party 415,000 Fair Value Adjustment (30,000 ) Balance – December 31, 2021 $ 385,000 Fair Value Adjustment (84,000 ) Balance – September 30 $ 301,000

Line of Credit - Related Party

Line of Credit - Related Party	9 Months Ended
	Sep. 30, 2022
Line of Credit - Related Party [Member]
Debt Instrument [Line Items]
Line of Credit - Related Party	5. Line of Credit – Related Party On July 25, 2022, the Company and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $60.0 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through July 31, 2024. Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a “Promissory Note,” and collectively, the “Promissory Notes”), and bear interest at the Applicable Federal Rate for short term loans (currently 2.84%), plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company’s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share. In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company’s common stock, par value $0.001 per share (collectively, the “Warrants”). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000 shares of Company’s Common Stock at an exercise price of $5.00 per share, which Warrant is exercisable upon issuance. Further, pursuant to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of the Company’s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price of the Company’s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029. The fair value of the 500,000 warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life of 7 years, volatility of 92%, risk free interest rate of 3.19% and zero dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the period ended September 30, 2022 of $39,000 was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through January 31, 2026.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units: Three Months Ended Nine Months Ended 2022 2021 2022 2021 in thousands Research and development $ 216 $ 91 $ 595 $ 247 General and administrative 465 496 1,591 1,175 Total stock-based compensation expense $ 681 $ 587 $ 2,186 $ 1,422 The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2021 through September 30, 2022: Shares Weighted Average Outstanding, December 31, 2021 4,895,561 $ 3.14 Granted 945,000 1.84 Exercised — — Options forfeited/cancelled (195,000 ) 2.21 Outstanding, September 30, 2022 5,645,561 $ 2.93 As of September 30, 2022, there was $2,735,000 of unrecognized compensation related to 2,694,584 unvested options, which is expected to be recognized over a weighted–average period of approximately 1.5 years. The weighted-average grant date fair value for options granted during the nine months ended September 30, 2022 was $1.37. The Company granted 945,000 stock options during the nine months ended September 30, 2022. The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used: Nine September 30, Nine September 30, 2022 2021 Risk-free interest rate 1.56 % 0.58 % Expected life of the options 5.6 years 6 years Expected volatility of the underlying stock 94 % 91 % Expected dividend rate 0 % 0 % In January 2022, one director elected to take a restricted stock grant in lieu of cash retainers for 2022. A total of 17,677 shares of restricted stock valued at approximately $35,000 is being amortized to expense on a straight-line basis until December 31, 2022 when the stock vests in full. In March 2021, one director elected to take a restricted stock grant in lieu of cash retainers for 2021. A total of 16,588 shares of restricted stock valued at approximately $35,000 is being amortized to expense on a straight-line basis until December 31, 2021 when the stock vested in full. In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80% will be paid in the form of deferred stock units (“ DSUs

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2022
Common Stock Warrants [Abstract]
Common Stock Warrants	7. Common Stock Warrants The following table summarizes the common stock warrant activity from December 31, 2020 through September 30, 2022: Shares Weighted Average Outstanding, December 31, 2021 10,857,964 $ 4.37 Granted 500,000 5.00 Exercised — — Forfeited/cancelled — — Outstanding, September 30, 2022 11,357,964 $ 4.40 The weighted average expiration of the warrants outstanding as of September 30, 2022 is 2.0 years.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2022
Loss Per Share [Abstract]
Loss Per Share	8. Loss Per Share Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share. Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows: September 30, 2022 September 30, 2021 Warrants to purchase shares of common stock 11,357,964 11,357,964 Options to purchase shares of common stock 5,645,561 4,660,561 Shares of common stock issuable upon conversion of convertible note payable 5,665,338 3,271,876 Shares of common stock issuable upon conversion of preferred stock 503,340 510,424 23,172,203 19,800,825

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2022
Common Stock [Abstract]
Common Stock	9. Common Stock 2020 At Market Issuance of Common Stock On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the “2020 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2020 At Market Agreement. There were no issuances of common stock under the 2020 At Market agreement during the nine months ended September 30, 2022. During the nine months ended September 30, 2021, the Company issued 845,214 For the nine months ended September 30, 2022 and 2021, the Company issued a total of 60,825 and 57,162 shares of common stock, respectively, for dividends on Series A and Series C Preferred Stock.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Other Legal Proceedings The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable and the related damages are estimable. There are no significant pending legal proceedings. Clinical Trial and Research Commitments The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be canceled at any time by providing thirty days’ notice.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	11. Leases The Company has one operating lease for its office space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive covenants. The amended lease provided for free rent for the first six and a half months September September other assets September accrued expenses other liabilities Maturity of operating lease as of September 30, 2022 in thousands: 2022 12 2023 50 2024 51 2025 18 Total 131 Less imputed interest 15 Present value of lease liability $ 116 The discount rate used in calculating the present value of the lease payments was 11%

Galectin Sciences LLC

Galectin Sciences LLC	9 Months Ended
	Sep. 30, 2022
Galectin Sciences LLC [Abstract]
Galectin Sciences LLC	12. Galectin Sciences LLC In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as well as the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Cumulatively, the Company has contributed a total of $3,204,000, including $180,000 for the nine months ended September September

Accrued Expenses and Other (Tab

Accrued Expenses and Other (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Expenses and Other [Abstract]
Accrued Expenses	Accrued expenses consist of the following: September 30, December 31, 2021 (in thousands) Legal and accounting fees $ 123 $ 68 Accrued compensation 751 728 Lease liability 39 8 Accrued research and development costs and other 6,323 6,359 Total $ 7,236 $ 7,163

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value of Financial Instruments [Abstract]
Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis at September 30, 2022 were as follows: Level 1 Level 2 Level 3 Total Derivative Liability – Contingent Interest April Note $ — $ — $ 373,000 $ 373,000 Derivative Liability – Contingent Interest September Note $ — $ — $ 177,000 $ 177,000 Derivative Liability – Contingent Interest December Note $ — $ — $ 301,000 $ 301,000
April Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Key Assumptions Used in Model at Inception	The April Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: September 30, Inception 2022 Stock Price $ 2.19 $ 1.63 Conversion Price of conversion feature $ 5.00 $ 5.00 Term 4 years 2.54 years Risk Free Interest Rate 0.59 % 4.24 % Credit Adjusted Discount Rate 7.60 % 17.42 % Volatility 88 % 83 % Dividend Rate 0 % 0 %
Roll Forward of Derivative Liability - Contingent Interest	The roll forward of the April Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of April convertible note payable – related party 420,000 Fair Value Adjustment 75,000 Balance – December 31, 2021 $ 495,000 Fair Value Adjustment (122,000 ) Balance – September 30, 2022 $ 373,000
September Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Key Assumptions Used in Model at Inception	The September Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: Inception September 30 2022 Stock Price $ 4.06 $ 1.63 Conversion Price of conversion feature $ 8.64 $ 8.64 Term 4 years 2.97 Risk Free Interest Rate 0.68 % 4.25 % Credit Adjusted Discount Rate 7.59 % 17.42 % Volatility 91 % 83 % Dividend Rate 0 % 0 %
Roll Forward of Derivative Liability - Contingent Interest	The roll forward of the September Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of September convertible note payable – related party 433,000 Fair Value Adjustment (183,000 ) Balance – December 31, 2021 $ 250,000 Fair Value Adjustment (73,000 ) Balance – September 30 $ 177,000
December Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Key Assumptions Used in Model at Inception	The December Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at inception, and at September 30, 2022 are as follows: September 30 Inception 2022 Stock Price $ 2.32 $ 1.63 Conversion Price of conversion feature $ 5.43 $ 5.43 Term 4 years 3.22 years Risk Free Interest Rate 1.04 % 4.24 % Credit Adjusted Discount Rate 8.54 % 17.42 % Volatility 86 % 81 % Dividend Rate 0 % 0 %
Roll Forward of Derivative Liability - Contingent Interest	The roll forward of the December Note derivative liability – contingent interest is as follows: Balance – December 31, 2020 $ — Issuance of September convertible note payable – related party 415,000 Fair Value Adjustment (30,000 ) Balance – December 31, 2021 $ 385,000 Fair Value Adjustment (84,000 ) Balance – September 30 $ 301,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Stock-Based Compensation [Abstract]
Components of Stock-Based Compensation Expense	Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units: Three Months Ended Nine Months Ended 2022 2021 2022 2021 in thousands Research and development $ 216 $ 91 $ 595 $ 247 General and administrative 465 496 1,591 1,175 Total stock-based compensation expense $ 681 $ 587 $ 2,186 $ 1,422
Stock Option Activity	The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2021 through September 30, 2022: Shares Weighted Average Outstanding, December 31, 2021 4,895,561 $ 3.14 Granted 945,000 1.84 Exercised — — Options forfeited/cancelled (195,000 ) 2.21 Outstanding, September 30, 2022 5,645,561 $ 2.93
Weighted Average Assumptions Used to Determine Fair Value of Options Granted	The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used: Nine September 30, Nine September 30, 2022 2021 Risk-free interest rate 1.56 % 0.58 % Expected life of the options 5.6 years 6 years Expected volatility of the underlying stock 94 % 91 % Expected dividend rate 0 % 0 %

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2022
Common Stock Warrants [Abstract]
Common Stock Warrant Activity	The following table summarizes the common stock warrant activity from December 31, 2020 through September 30, 2022: Shares Weighted Average Outstanding, December 31, 2021 10,857,964 $ 4.37 Granted 500,000 5.00 Exercised — — Forfeited/cancelled — — Outstanding, September 30, 2022 11,357,964 $ 4.40

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Loss Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share	Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows: September 30, 2022 September 30, 2021 Warrants to purchase shares of common stock 11,357,964 11,357,964 Options to purchase shares of common stock 5,645,561 4,660,561 Shares of common stock issuable upon conversion of convertible note payable 5,665,338 3,271,876 Shares of common stock issuable upon conversion of preferred stock 503,340 510,424 23,172,203 19,800,825

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Maturity of Operating Lease	Maturity of operating lease as of September 30, 2022 in thousands: 2022 12 2023 50 2024 51 2025 18 Total 131 Less imputed interest 15 Present value of lease liability $ 116

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jul. 25, 2022	Dec. 31, 2021
Basis of Presentation [Abstract]
Cash and cash equivalents	$ 15,831		$ 39,648
Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member]
Basis of Presentation [Abstract]
Line of credit		$ 60,000

Accrued Expenses and Other (Det

Accrued Expenses and Other (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses and Other [Abstract]
Legal and accounting fees	$ 123,000	$ 68,000
Accrued compensation	751,000	728,000
Lease liability	39,000	8,000
Accrued research and development costs and other	6,323,000	6,359,000
Total	$ 7,236,000	$ 7,163,000

Convertible Notes Payable - R_2

Convertible Notes Payable - Related Party (Details)							3 Months Ended		9 Months Ended		17 Months Ended
	Dec. 30, 2025 USD ($)	Sep. 17, 2025 USD ($)	Apr. 16, 2025 USD ($)	Dec. 20, 2021 USD ($) PromissoryNote $ / shares	Sep. 17, 2021 USD ($) PromissoryNote loan	Apr. 16, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)
Convertible Notes Payable - Related Party [Abstract]
Fair value of derivative liability							$ 850,000		$ 850,000		$ 850,000	$ 1,130,000
Change in fair value of derivative							$ (224,000)	$ (166,000)	280,000	$ (338,000)
April Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Change in fair value of derivative									(122,000)
Amortization of debt discount									420,000
Additional interest expense									$ 79,000
April Note [Member] | Forecast [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note payable repayment			$ 10,000,000
April Note [Member] | Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Debt financing arrangement						$ 10,000,000
Convertible note principal						$ 10,000,000
Maturity date									Apr. 16, 2025
Conversion price (in dollars per share) | $ / shares							$ 5		$ 5		$ 5
Interest rate compounded annually							2%		2%		2%
Accrued interest expense							$ 50,000		$ 150,000		$ 292,000
Additional interest rate per quarter						2.50%
Additional interest rate per annum from issuance date to maturity date period						10%
Fair value of derivative liability						$ 420,000	$ 373,000		373,000		$ 373,000
September Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Change in fair value of derivative									(73,000)
Amortization of debt discount									433,000
Additional interest expense									$ 81,000
September Note [Member] | Forecast [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note payable repayment		$ 10,000,000
September Note [Member] | Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Debt financing arrangement					$ 20,000,000
Maturity date									Sep. 17, 2025
Number of loans closing | loan					2
Number of promissory notes evidenced by loans agreement | PromissoryNote					2
Number of promissory notes executed | PromissoryNote					2
Conversion price (in dollars per share) | $ / shares							$ 8.64		$ 8.64		$ 8.64
Interest rate compounded annually							2%		2%		2%
Accrued interest expense							$ 50,000		$ 150,000		$ 207,000
Additional interest rate per quarter					2.50%
Additional interest rate per annum from issuance date to maturity date period					10%
Fair value of derivative liability					$ 433,000		177,000		$ 177,000		177,000
First Closing [Member] | Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Debt financing arrangement					$ 10,000,000
Second Closing [Member] | Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Debt financing arrangement				$ 10,000,000
December Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note principal				$ 10,000,000
Maturity date									Dec. 20, 2025
Number of promissory notes evidenced by loans agreement | PromissoryNote				2
Conversion price (in dollars per share) | $ / shares				$ 5.43
Interest rate compounded annually				2%
Accrued interest expense							50,000		$ 150,000		156,000
Additional interest rate per quarter				2.50%
Additional interest rate per annum from issuance date to maturity date period				10%
Fair value of derivative liability				$ 415,000			$ 301,000		301,000		$ 301,000
Change in fair value of derivative									(85,000)
Amortization of debt discount									415,000
Additional interest expense									$ 78,000
December Note [Member] | Forecast [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note payable repayment	$ 10,000,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	$ 850,000	$ 1,130,000
April Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	373,000	495,000	$ 0
September Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	177,000	250,000	0
December Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	301,000	385,000	$ 0
Recurring [Member] | Level 2 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Assets	0	0
Liabilities	0	$ 0
Recurring [Member] | April Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	373,000
Recurring [Member] | April Note [Member] | Level 1 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | April Note [Member] | Level 2 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | April Note [Member] | Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	373,000
Recurring [Member] | September Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	177,000
Recurring [Member] | September Note [Member] | Level 1 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | September Note [Member] | Level 2 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | September Note [Member] | Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	177,000
Recurring [Member] | December Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	301,000
Recurring [Member] | December Note [Member] | Level 1 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | December Note [Member] | Level 2 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	0
Recurring [Member] | December Note [Member] | Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	$ 301,000

Fair Value of Financial Instr_4

Fair Value of Financial Instruments, Key Assumptions (Details)				9 Months Ended
	Dec. 20, 2021 shares	Sep. 17, 2021	Apr. 16, 2021	Sep. 30, 2022 shares
Stock Price [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			2.19	1.63
Stock Price [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		4.06		1.63
Stock Price [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	2.32			1.63
Conversion Price of Conversion Feature [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			5	5
Conversion Price of Conversion Feature [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		8.64		8.64
Conversion Price of Conversion Feature [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	5.43			5.43
Term [Member] | April Note [Member]
Key Assumptions [Abstract]
Term			4 years	2 years 6 months 14 days
Term [Member] | September Note [Member]
Key Assumptions [Abstract]
Term		4 years		2 years 11 months 19 days
Term [Member] | December Note [Member]
Key Assumptions [Abstract]
Term	4 years			3 years 2 months 19 days
Risk Free Interest Rate [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			0.0059	0.0424
Risk Free Interest Rate [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		0.0068		0.0425
Risk Free Interest Rate [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.0104			0.0424
Credit Adjusted Discount Rate [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			0.076	0.1742
Credit Adjusted Discount Rate [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		0.0759		0.1742
Credit Adjusted Discount Rate [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.0854			0.1742
Volatility [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			0.88	0.83
Volatility [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		0.91		0.83
Volatility [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.86			0.81
Dividend Rate [Member] | April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input			0	0
Dividend Rate [Member] | September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input		0		0
Dividend Rate [Member] | December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0			0

Fair Value of Financial Instr_5

Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Roll Forward of Derivative Liability [Roll Forward]
Balance	$ 1,130,000
Fair Value Adjustment	(280,000)	$ 338,000
Balance	850,000		$ 1,130,000
April Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	495,000	0	0
Issuance of convertible note payable - related party			420,000
Fair Value Adjustment	(122,000)		75,000
Balance	373,000		495,000
September Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	250,000	0	0
Issuance of convertible note payable - related party			433,000
Fair Value Adjustment	(73,000)		(183,000)
Balance	177,000		250,000
December Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	385,000	$ 0	0
Issuance of convertible note payable - related party			415,000
Fair Value Adjustment	(84,000)		(30,000)
Balance	$ 301,000		$ 385,000

Line of Credit - Related Party

Line of Credit - Related Party (Details) - USD ($)		9 Months Ended
	Jul. 25, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Line of Credit - Related Party [Abstract]
Common stock, par value (in dollars per share)		$ 0.001		$ 0.001
Fair value of warrants		$ 500,000
Warrants issuance value		$ 738,000
Expected life		5 years 7 months 6 days	6 years
Expected volatility		94%	91%
Risk free interest rate		1.56%	0.58%
Expected dividend		0%	0%
Amortization of interest expense		$ 39,000
Warrants [Member]
Line of Credit - Related Party [Abstract]
Expected life		7 years
Expected volatility		92%
Risk free interest rate		3.19%
Expected dividend		0%
Richard E. Uihlein [Member]
Line of Credit - Related Party [Abstract]
Common stock, par value (in dollars per share)	$ 0.001
Exercise price of warrant (in dollars per share)	$ 5
Percentage of warrants equal to the closing price of common stock	150%
Warrants expiry date	Jul. 31, 2029
Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member]
Line of Credit - Related Party [Abstract]
Line of credit	$ 60,000,000
Short term borrowing interest rate	2.84%
Additional short term borrowing interest rate	2%
Maturity date	Jan. 31, 2026
Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member] | Minimum [Member]
Line of Credit - Related Party [Abstract]
Share price (in dollars per share)	$ 3
Richard E. Uihlein [Member] | Unsecured Convertible Promissory Note [Member] | Maximum [Member]
Line of Credit - Related Party [Abstract]
Share price (in dollars per share)	$ 10
Common Stock [Member] | Richard E. Uihlein [Member]
Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)	1,700,000
Common Stock [Member] | Richard E. Uihlein [Member] | Maximum [Member]
Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)	500,000
Warrants to purchase additional common stock (in shares)	1,200,000

Stock-Based Compensation, Compo

Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	$ 681	$ 587	$ 2,186	$ 1,422
Research and Development [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	216	91	595	247
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	$ 465	$ 496	$ 1,591	$ 1,175

Stock-Based Compensation, Stock

Stock-Based Compensation, Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Stock Option Activity [Roll Forward]
Outstanding at beginning of period (in shares) | shares	4,895,561
Granted (in shares) | shares	945,000
Exercised (in shares) | shares	0
Forfeited/cancelled (in shares) | shares	(195,000)
Outstanding at end of period (in shares) | shares	5,645,561
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 3.14
Granted (in dollars per share) | $ / shares	1.84
Exercised (in dollars per share) | $ / shares	0
Forfeited/cancelled (in dollars per share) | $ / shares	2.21
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 2.93
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]
Unrecognized compensation cost | $	$ 2,735,000
Unvested options (in shares) | shares	2,694,584
Unrecognized compensation cost, recognition period	1 year 6 months
Weighted-average grant-date fair value of options granted (in dollars per share) | $ / shares	$ 1.37

Stock-Based Compensation, Weigh

Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Weighted Average Assumptions for Stock Options Granted [Abstract]
Risk-free interest rate	1.56%	0.58%
Expected life of the options	5 years 7 months 6 days	6 years
Expected volatility of the underlying stock	94%	91%
Expected dividend rate	0%	0%

Stock-Based Compensation, Restr

Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2022 USD ($) Director shares	Mar. 31, 2021 USD ($) Director shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares
Restricted Stock Grants [Abstract]
Amortized expense			$ 681,000	$ 587,000	$ 2,186,000	$ 1,422,000
Unrecognized compensation cost			2,735,000		2,735,000
Restricted Stock [Member]
Restricted Stock Grants [Abstract]
Number of directors | Director	1	1
Restricted stock awards granted (in shares) | shares	17,677	16,588
Amortized expense	$ 35,000	$ 35,000
Chief Executive Officer [Member]
Restricted Stock Grants [Abstract]
Unrecognized compensation cost			$ 0		$ 0
Chief Executive Officer [Member] | Deferred Bonus [Member]
Restricted Stock Grants [Abstract]
Percentage of base salary paid in cash					20%
Percentage of base salary paid in deferred stock units					80%
Percentage of DSUs shall be credited on March 1, 2021			25%		25%
Percentage of DSUs shall be credited on September 1, 2021			25%		25%
Percentage of DSUs shall be credited on March 1, 2024			50%		50%
Stock based compensation expense					$ 313,000		$ 200,000
Common stock reserved for future issuance (in shares) | shares					186,647		103,627
Common Stock Weighted average Grant Date fair Value (in dollars per share) | $ / shares					$ 1.68		$ 1.93
Reclassification of accrued compensation to additional paid in capital					$ 200,000

Common Stock Warrants (Details)

Common Stock Warrants (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Weighted Average Exercise Price [Abstract]
Weighted average expiration term of warrants outstanding	2 years
Warrants [Member]
Common Stock Warrants shares [Roll Forward]
Outstanding at beginning of period (in shares) | shares	10,857,964
Granted (in shares) | shares	500,000
Exercised (in shares) | shares	0
Forfeited/cancelled (in shares) | shares	0
Outstanding at end of period (in shares) | shares	11,357,964
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 4.37
Granted (in dollars per share) | $ / shares	5
Exercised (in dollars per share) | $ / shares	0
Forfeited/cancelled (in dollars per share) | $ / shares	0
Outstanding at end of period (in dollars per share) | $ / shares	$ 4.4

Loss Per Share (Details)

Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	23,172,203	19,800,825
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	11,357,964	11,357,964
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	5,645,561	4,660,561
Convertible Note Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	5,665,338	3,271,876
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	503,340	510,424

Common Stock (Details)

Common Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Common Stock [Abstract]
Issuance of common stock (in shares)	59,426,005		59,341,305
Net proceeds from issuance of common stock	$ 0	$ 6,815,000
2020 Market Agreement [Member]
Common Stock [Abstract]
Aggregate offering price	$ 40,000,000
Percentage of commission rate to be paid to sales agent	3%
Issuance of common stock (in shares)	0	845,214
Net proceeds from issuance of common stock	$ 3,864,000
2020 Market Agreement [Member] | Series A and Series C Preferred Stock [Member]
Common Stock [Abstract]
Common stock issued for dividends (in shares)	60,825	57,162

Commitments and Contingencies (

Commitments and Contingencies (Details)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies [Abstract]
Contract cancelation notice period	30 days

Leases (Details)

Leases (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) Lease	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Lease Commitments [Abstract]
Number of operating leases | Lease	1
Term of contract	38 months
Free rent period	6 months 15 days
Security deposit	$ 6,000
Right to use lease asset	$ 93,000
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets
Current lease liability	$ 39,000		$ 8,000
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current
Long term lease liability	$ 77,000
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities
Maturity of Operating Lease [Abstract]
2022	$ 12,000
2023	50,000
2024	51,000
2025	18,000
Total	131,000
Less imputed interest	15,000
Present value of lease liability	$ 116,000
Discount rate on present value of lease payments	11%
General and Administrative Expense [Member]
Lease Commitments [Abstract]
Lease cost	$ 32,000	$ 32,000

Galectin Sciences LLC (Details)

Galectin Sciences LLC (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended		102 Months Ended
	Jan. 31, 2014	Dec. 31, 2014	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Amount expanded in cash			$ (23,817,000)	$ 9,458,000
Galectin Sciences, LLC [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Initial cash investment	$ 400,000
Equity ownership percentage			85.20%
Amount expanded in cash		$ 400,000
Contribution for expenses			$ 180,000		$ 3,204,000
Galectin Sciences, LLC [Member] | SBH [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Equity ownership percentage	50%
Contribution for expenses			$ 158,000
Galectin Sciences, LLC [Member] | SBH [Member] | IPR&D [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Estimated fair value of asset contributed to joint venture	$ 400,000